(0.17%) 5 140.25 points
(0.09%) 38 477 points
(0.28%) 17 897 points
(-0.36%) $83.55
(1.72%) $1.956
(0.12%) $2 350.10
(0.39%) $27.64
(1.34%) $934.45
(-0.06%) $0.934
(-0.19%) $11.00
(-0.17%) $0.799
(1.31%) $93.08
Live Chart Being Loaded With Signals
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products...
Stats | |
---|---|
本日の出来高 | 26 806.00 |
平均出来高 | 51 037.00 |
時価総額 | 406.69B |
EPS | €8.63 ( 2023-06-30 ) |
Last Dividend | €3.00 ( 2023-08-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 22.91 |
ATR14 | €2.62 (2.86%) |
ボリューム 相関
Novo Nordisk A/S 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Novo Nordisk A/S 相関 - 通貨/商品
Novo Nordisk A/S 財務諸表
Annual | 2022 |
収益: | €176.95B |
総利益: | €148.51B (83.92 %) |
EPS: | €24.51 |
FY | 2022 |
収益: | €176.95B |
総利益: | €148.51B (83.92 %) |
EPS: | €24.51 |
FY | 2021 |
収益: | €140.80B |
総利益: | €117.14B (83.20 %) |
EPS: | €20.79 |
FY | 2020 |
収益: | €126.95B |
総利益: | €106.01B (83.51 %) |
EPS: | €18.05 |
Financial Reports:
No articles found.
Novo Nordisk A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€4.25 (N/A) |
€0 (N/A) |
€8.15 (N/A) |
€0 (N/A) |
€3.00 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.670 | 2002-03-13 |
Last Dividend | €3.00 | 2023-08-18 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | €100.58 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.88 | -- |
Div. Sustainability Score | 6.14 | |
Div.Growth Potential Score | 4.38 | |
Div. Directional Score | 5.26 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
KRN.DE | Ex Dividend Knight | 2023-05-24 | Annually | 0 | 0.00% | |
TTK.DE | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
DWD.DE | Ex Dividend Junior | 2023-07-28 | Quarterly | 0 | 0.00% | |
MZX.DE | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
8TRA.DE | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
XGR2.DE | Ex Dividend Junior | 2023-06-08 | Annually | 0 | 0.00% | |
FPMB.DE | Ex Dividend King | 2023-10-12 | Quarterly | 0 | 0.00% | |
PFE.DE | Ex Dividend Knight | 2023-07-27 | Quarterly | 0 | 0.00% | |
ASME.DE | Ex Dividend Knight | 2023-08-01 | Semi-Annually | 0 | 0.00% | |
HNR1.DE | Ex Dividend Junior | 2023-05-04 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.351 | 1.500 | 2.98 | 4.47 | [0 - 0.5] |
returnOnAssetsTTM | 0.251 | 1.200 | 1.635 | 1.962 | [0 - 0.3] |
returnOnEquityTTM | 0.869 | 1.500 | 1.460 | 2.19 | [0.1 - 1] |
payoutRatioTTM | 0.422 | -1.000 | 5.78 | -5.78 | [0 - 1] |
currentRatioTTM | 0.824 | 0.800 | -0.880 | -0.704 | [1 - 3] |
quickRatioTTM | 0.635 | 0.800 | -0.971 | -0.777 | [0.8 - 2.5] |
cashRatioTTM | 0.175 | 1.500 | -0.141 | -0.211 | [0.2 - 2] |
debtRatioTTM | 0.0884 | -1.500 | 8.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -18.83 | 1.000 | -8.08 | -8.08 | [3 - 30] |
operatingCashFlowPerShareTTM | 23.78 | 2.00 | 2.07 | 4.15 | [0 - 30] |
freeCashFlowPerShareTTM | 17.38 | 2.00 | 1.308 | 2.62 | [0 - 20] |
debtEquityRatioTTM | 0.285 | -1.500 | 8.86 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.841 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.392 | 1.000 | 4.16 | 4.16 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.01 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.715 | 0.800 | 8.57 | 6.85 | [0.5 - 2] |
Total Score | 6.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.52 | 1.000 | 6.01 | 0 | [1 - 100] |
returnOnEquityTTM | 0.869 | 2.50 | 4.51 | 2.19 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 17.38 | 2.00 | 4.21 | 2.62 | [0 - 30] |
dividendYielPercentageTTM | 0.440 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 23.78 | 2.00 | 2.07 | 4.15 | [0 - 30] |
payoutRatioTTM | 0.422 | 1.500 | 5.78 | -5.78 | [0 - 1] |
pegRatioTTM | 0.142 | 1.500 | -2.38 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.496 | 1.000 | 0.0917 | 0 | [0.1 - 0.5] |
Total Score | 4.38 |
Novo Nordisk A/S
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。